French Cancer Centre conducts clinical trial of Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
Photo by Ousa Chea
Centre Oscar Lambret is recruiting patients for the clinical trial of Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC).
The planned interventions are collection of biological samples at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib treatment with a clinical-biological database.
The aim of this study is to describe molecular changes associated with resistance to Palbociclib at the individual level and describe longitudinal changes in the profile of tumor, VOCs and exosomes according to treatment response.
The study will take place at the Centre Oscar Lambret, Lille, France.
Among the criteria that allow participation, the following are indicated:
- Women over 18 years old
- With histologically proven breast cancer, positives hormones receptors and negative HER2
- Advanced disease (metastases or non-resequable locoregional disease), from the 1st to the 4th line
- With an indication for hormone therapy associated with the CDK4/6 inhibitor Palbociclib
Patients with the following pathologies:
- Neoadjuvant or adjuvant treatment for localized breast cancer
- Metastatic breast cancer beyond the forth lineare excluded from participation.
Intrapatient variation in molecular profiles at progression compared to baseline is on of primary outcome measure.
The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04653740
